USO 23076

A PHASE III, MULTICENTER, RANDOMIZED, OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

• Previously untreated participants with CD20 positive
LBCL
• IPI score 2-5
• ECOG status of ≤ 2
• At least one bi-dimensionally measurable lesion, defined
as > 1.5 cm in its longest dimension as measured by CT
or MRI
• Patients with prior solid organ transplantation are
excluded
• Patients with contraindication to any of the individual
components of Pola-R-CHP or Glofitamab, including
prior receipt of anthracyclines are excluded

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg